BIOMAT Database Logo BIOMAT Database Logo

Failure of long term luteinising hormone releasing hormone to suppress testosterone. 1984

N Faure

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone

Related Publications

N Faure
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
September 1984, British medical journal (Clinical research ed.),
N Faure
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
August 1984, British medical journal (Clinical research ed.),
N Faure
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
August 1985, British medical journal (Clinical research ed.),
N Faure
Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
October 1988, British journal of urology,
N Faure
Long-term effects of buserelin on plasma testosterone and luteinising hormone concentrations.
November 1985, Lancet (London, England),
N Faure
Luteinising hormone releasing hormone (LHRH).
February 1978, Drug and therapeutics bulletin,
N Faure
Luteinising-hormone-releasing hormone and cryptorchidism.
July 1986, Lancet (London, England),
N Faure
Contraceptive properties of luteinising hormone releasing hormone.
October 1979, Lancet (London, England),
N Faure
Intranasal application of luteinising-hormone releasing hormone.
June 1973, Lancet (London, England),
N Faure
Failure of high-dose sustained release luteinizing hormone releasing hormone agonist (buserelin) plus oral testosterone to suppress male fertility.
December 1985, Clinical endocrinology,
Copied contents to your clipboard!